In contrast, metformin—which has been recommended as a first-line treatment to T2DM patients who have cardiovascular risks [25,26]—enhances energy expenditure, suppresses hepatic gluconeogenesis, and induces insulin sensitization through AMP-activated protein kinase (AMPK) activation. The gene discussed is INS; the disease is type 2 diabetes mellitus.